Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
US and EU regulatory authorities accept oral BG-12 marketing applications for review
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Neuroprotection in a novel mouse model of multiple sclerosis.
Estrogen and testosterone therapies in multiple sclerosis.
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® (glatiramer acetate injection) 40mg/mL
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kcyB (NF-kcyB) and Extracellular Signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress activated kinase 1 (MSK1) signaling.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
Breastfeeding is not related to postpartum relapses in multiple sclerosis.
Masitinib mesylate application for conditional approval
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
“Veterinary Medicines” page
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis.

Pages